Krassas Gerasimos E, Pontikides Nikolaos, Loustis Kostas, Koliakos Georgios, Constantinidis Theodoros, Panidis Dimitrios
Department of Endocrinology, Diabetes and Metabolism, Panagia General Hospital, Thessaloniki, Greece.
Eur J Endocrinol. 2005 Aug;153(2):217-21. doi: 10.1530/eje.1.01963.
Resistin is a recently discovered peptide hormone that belongs to a family of tissue-specific resistin-like molecules. To date, very few studies have reported on resistin concentrations in hyperthyroid patients, and they present controversial results.
To undertake a controlled, prospective study to investigate resistin concentrations in hyperthyroidism before and after restoration of euthyroidism and to correlate the results with body weight, body fat, waist circumference and body mass index (BMI).
A total of 43 hyperthyroid patients (12 men and 31 women) were investigated, in addition to 23 controls. Anthropometric parameters and resistin concentrations were measured. All the patients commenced taking antithyroid drugs and 3-4 months later the same investigations were performed in 36 of the 43 individuals.
Hyperthyroid patients exhibited increased resistin concentrations in comparison with controls. Normalization of thyroid hormones was accompanied by a significant decrease in resistin concentration. A sex difference was also found, men showing a significant decrease in resistin concentrations, whereas in women no such difference was found. Resistin concentrations did not correlate with different anthropometric parameters, age and thyroid hormones, either before or after treatment.
This study demonstrates for the first time that, although resistin concentrations are increased in hyperthyroidism, they are not associated with body weight, body fat, waist circumference or BMI, which makes it unlikely that resistin plays a crucial part in thermogenesis and energy homeostasis in thyrotoxic patients.
抵抗素是一种最近发现的肽类激素,属于组织特异性抵抗素样分子家族。迄今为止,关于甲状腺功能亢进患者抵抗素浓度的研究报道极少,且结果存在争议。
进行一项对照性前瞻性研究,以调查甲状腺功能恢复正常前后甲状腺功能亢进患者的抵抗素浓度,并将结果与体重、体脂、腰围和体重指数(BMI)进行关联。
除23名对照者外,共对43例甲状腺功能亢进患者(12名男性和31名女性)进行了研究。测量了人体测量学参数和抵抗素浓度。所有患者开始服用抗甲状腺药物,3 - 4个月后,对43例患者中的36例进行了相同的检查。
与对照组相比,甲状腺功能亢进患者的抵抗素浓度升高。甲状腺激素正常化伴随着抵抗素浓度的显著降低。还发现了性别差异,男性抵抗素浓度显著降低,而女性未发现此类差异。治疗前后,抵抗素浓度与不同的人体测量学参数、年龄和甲状腺激素均无相关性。
本研究首次证明,尽管甲状腺功能亢进时抵抗素浓度升高,但它与体重、体脂、腰围或BMI无关,这使得抵抗素不太可能在甲状腺毒症患者的产热和能量稳态中起关键作用。